Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Aug 18, 2023 11:36am
149 Views
Post# 35594921

RE:RE:RE:RE:RE:RE:Antibody-Drug-Conjugate (ADC) company reports patient death

RE:RE:RE:RE:RE:RE:Antibody-Drug-Conjugate (ADC) company reports patient death August 18, 2023 - Seagen released Phase III results on Wednesday (August 16) for its tyrosine kinase inhibitor Tukysa (tucatinib), in combination with Genentech’s antibody-drug conjugate Kadcyla (ado-trastuzumab emtansine), which met its primary endpoint of progression-free survival in HER-2 positive breast cancer patients.

Serious adverse reactions occurred in the study in 26% of patients, according to Seagen, with the most common being diarrhea, vomiting, nausea, abdominal pain, and seizure. Fatal adverse reactions occurred in 2% of patients receiving Tukysa, including sudden death, sepsis, dehydration, and cardiogenic shock.

Tukysa is a tyrosine kinase inhibitor which works by inhibiting phosphorylation of HER2 and HER3, a well-established biomarker of poor outcomes in gastric, breast, and colon cancers. This results in anti-tumor activity in HER-2 expressing tumor cells.


https://www.biospace.com/article/seagen-touts-phase-iii-data-for-breast-cancer-combo-therapy-/

<< Previous
Bullboard Posts
Next >>